TRIMETHOPRIM (trimethoprim) by Dr. Reddy's Laboratories is dihydrofolate reductase inhibitors [moa]. First approved in 1982.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
Trimethoprim is a dihydrofolate reductase inhibitor antibacterial agent administered orally as a tablet for treating bacterial infections. It works by inhibiting bacterial dihydrofolate reductase, disrupting folate metabolism and DNA synthesis. This generic small molecule has been a foundational antibiotic since its 1982 approval.
Mature generic product with minimal Part D spending and low claim volume indicates a contracted team managing a legacy asset with limited growth opportunity.
Dihydrofolate Reductase Inhibitors
Dihydrofolate Reductase Inhibitor Antibacterial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers
Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
Worked on TRIMETHOPRIM at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on trimethoprim offers limited career advancement as a mature generic with minimal commercial infrastructure and no clinical development. Positions are typically operational or compliance-focused with constrained visibility and limited promotion pathways within a pharma company.